Since the approval of ICIs in 2016, cohort studies leveraging data from US community centers have demonstrated a median rwOS ranging from 16 to 21 months for 1L PD-1/PD-L1 inhibitor monotherapy and 15 to 19 months for 1L PD-1/PD-L1 inhibitor combination with PBC (28, 29). This evidence concerns the gene CD274 and primary biliary cholangitis.